Study on the mechanism of lupenone for treating type 2 diabetes by integrating pharmacological evaluation and network pharmacology
Autor: | Feng, Xu, Mei, Zhang, Hongmei, Wu, Yuanmin, Wang, Ye, Yang, Xiangpei, Wang |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Pharmaceutical Biology. 60:997-1010 |
ISSN: | 1744-5116 1388-0209 |
Popis: | Lupenone (LUP) is the active ingredient ofAnimal experiments combined with network pharmacology were used to explore the mechanism of LUP for treating diabetes.Insulin resistance (IR) in male Sprague-Dawley rats with type 2 diabetic was induced using a high-fat diet and streptozotocin. The selected rats were divided into normal group, model group, positive group and LUP (2.0, 4.0 and 8.0 mg/kg) groups, and orally administrated twice daily with Tween 80, rosiglitazone or LUP. Fasting blood glucose (FBG), oxidative stress index, blood lipids and IR-related targets were detected. A network pharmacology analysis was performed.Compared to the model group, LUP (8.0 mg/kg) significantly decreased the levels of FBG (22.3%), LEP (9.5%), HbA1c (14.9%) and MDA (12.3%), increased the ADPN (24.2%) levels and GSH-PX activity (12.4%) (The mechanism of LUP for treating diabetes is related to improving IR. LUP has the potential to be developed as a new drug for treating type 2 diabetes. |
Databáze: | OpenAIRE |
Externí odkaz: |